Drug Formulation - pitfalls to avoid from the start

80-% 90% of drug candidates in the R&D pipeline face formulation challenges.
An appropriate formulation will dictate the faith of the drug. No matter how efficient the drug can be in-vitro if the in-vivo formulation does not fit- it takes out that drug from your pipeline.

The questions we are going to address in this meetup will help to organize our thoughts and conception about the formulation challenges.

1. When do we need to think about formulation?
2. Does the formulation for in-vivo is needed? Or it is a waste of time to invest in the formulation development in that early stage?
3. Is there a faster and cheaper way to test formulation for in-vivo?
4. Is there a correlation between the in-vivo formulation and phase I studies?
5. What the difference in formulation for in-vivo and Phase I?
6. When is the best time to invest in "real" formulation development, Phase I, II or just III?
7. How much it may cost to develop a formulation in each Phase?
8. What formulation development is the cost-efficient for each phase?
9. What are the considerations that should be taken into an account when choosing the right formulation?

Many more questions will be addressed during the evening, come prepared.

The speakers:
"Pre-formulation: when to start thinking of the initial formulation"
Galia Temtsin Krayz, PhD- CEO at Formulex

"Formulation challenges during drug development phases"
Shimon Amsalem, PhD. Shimon serves as a Chief Scientist at SpacePharma and a Chief Scientist at Delivery Technologies, ADAMA

"Crossing the BBB- towards solving the challenges"
Prof. Ilana Gozes. Ilana is a Professor of Clinical Biochemistry at the Sackler Faculty of Medicine in Tel Aviv University and a CSO in Coronis Neuroscience.

Yours,

Helen Domeshek, PhD
Business Development Manager
...............................................
Recipharm Israel
Address: Hamazmera 9 | Ness Ziona | Israel
Phone: +972 8 9293843 (Direct) | +972-54-764-3763 (Mobile)
www.recipharm.com